Home

Search database
Insert profile

Contact
Login

    Partner Search profiles

Show all
Search

 Albania
 Argentina19 
 Austria44 
 Belarus18 
 Belgium115 
 Bosnia Herzegovina
 Brasil
 Bulgaria28 
 Chile
 China
 Colombia
 Croatia23 
 Cyprus12 
 Czech Republic13 
 Denmark13 
 Dominican Republic
 Ecuador
 Egypt16 
 Estonia20 
 Faroe Islands
 Finland11 
 France102 
 Germany84 
 Greece70 
 Hungary22 
 Iceland23 
 India
 Indonesia
 Ireland85 
 Israel27 
 Italy140 
 Kazakhstan
 Korea
 Latvia14 
 Lithuania11 
 Luxembourg
 Malta
 North Macedonia
 Malaysia
 Mexico25 
 Moldova
 Montenegro
 Netherlands20 
 Norway17 
 Peru
 Poland33 
 Portugal73 
 Romania18 
 Russia14 
 Serbia
 Slovenia21 
 Slovak Republic28 
 South Africa13 
 Spain219 
 Sweden
 Switzerland39 
 Taiwan23 
 Tunesia
 Turkey158 
 Ukraine
 United Kingdom161 
 Uruguay
 USA
 Uzbekistan
 Other11 
 Total1893 

Partner Search Profiles

OrganisationSC ARCIRE APPLIED SCIENCE SRLD

Country

Romania

Inserted:

21 Jun 2019

Expires:

21 Dec 2021

Role

Partner

Project Title

Dual chamber microfluidic point-of-care smart device for testing the celular response to d...

H2020 Call Topic


Description

The project aims to develop a system for monitoring the efficacy of drugs released by an Au-OLC nano-conjugate
on circulating tumor cells (CTC) extracted from the bloodstream and then grown. The system is based on the
idea that photo activity of irradiated nanoparticles can control the induction of ROS (reactive oxygen species) in
cancer cells. OLC super-capacity properties attached to irradiate AuNPs can stimulate normal cell viability and,
at the same time, inhibit growth of cancer cells. Therefore, we can expect the Au-OLC nano-conjugate to
produce an increase in ROS yield and to be efficiently eliminated from the tissues.
The use of the AuNPs-OLC nano- conjugate as a nano- carrier element allows the release of drugs at lower
concentrations. High biocompatibility and multi-valent structure of the nano -conjugate surface provide more
possibilities for permeability in cell membranes.
Evaluation of drug efficacy on CTC cells can be performed using a microfluidic device. The device can monitor
the direction of cellular motion in an uneven field. The bicameral arrangement of the device can differentiate
the change in the physiological state of drug-treated cells as compared to untreated cells.
The device can be easily interfaced with intelligent devices and also integrated into laboratory equipment at a
low cost.

Expertise sought/offered

We are looking to sign a research cooperation agreement with partners in order to access a research grant under
the Horizon 2020 finance programmes, to go through clinical phases, develop and commercialize the device
Our partners should fulfill the following profiles:
A manufacturing company for the microfabrication of the dielectrophoretic microfluidic device with the 3D
microelectrode array architecture and a data acquisition system;
An ICT company for developing the hardware and software architecture for data acquisition and interface (GUI)
with mobile devices that allows data processing and management and storage of data;
An oncology center for testing the device on human blood in vitro studies.
A specialized large pharmaceutical company to promote and market the device on the markets.

Tasks offered/requested

* Conduct surveys
* Dissemination/communication activities
* Quality management
* Project management (as Work Package leader / Task leader)
* Design a business plan
* Develop an ICT application
* Organise a webinar



Partnersearch Profile is expired


Contact | Disclaimer | Privacy | Adminlogin

Copyright (2015 - 2019) - Net4Society Research Directory